VICINI, Roberto
 Distribuzione geografica
Continente #
NA - Nord America 2.318
EU - Europa 1.825
AS - Asia 1.244
SA - Sud America 174
AF - Africa 24
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
AN - Antartide 1
Totale 5.591
Nazione #
US - Stati Uniti d'America 2.277
IT - Italia 677
CN - Cina 447
GB - Regno Unito 425
SG - Singapore 393
SE - Svezia 155
BR - Brasile 141
IE - Irlanda 140
HK - Hong Kong 139
DE - Germania 123
VN - Vietnam 80
RU - Federazione Russa 63
FI - Finlandia 47
KR - Corea 41
UA - Ucraina 35
ID - Indonesia 33
NL - Olanda 32
IN - India 31
FR - Francia 27
MX - Messico 19
CA - Canada 18
BG - Bulgaria 15
TR - Turchia 15
AR - Argentina 14
BE - Belgio 12
JP - Giappone 12
LT - Lituania 12
PL - Polonia 10
MK - Macedonia 9
AT - Austria 8
PH - Filippine 8
CO - Colombia 7
ES - Italia 7
ZA - Sudafrica 7
CH - Svizzera 6
GR - Grecia 6
MY - Malesia 6
SA - Arabia Saudita 6
CL - Cile 5
CZ - Repubblica Ceca 5
BD - Bangladesh 4
IQ - Iraq 4
NG - Nigeria 4
EC - Ecuador 3
TN - Tunisia 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
EG - Egitto 2
IL - Israele 2
IR - Iran 2
IS - Islanda 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
LA - Repubblica Popolare Democratica del Laos 2
LY - Libia 2
MA - Marocco 2
OM - Oman 2
PK - Pakistan 2
PY - Paraguay 2
RS - Serbia 2
UZ - Uzbekistan 2
VE - Venezuela 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AP - ???statistics.table.value.countryCode.AP??? 1
AQ - Antartide 1
BJ - Benin 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
HN - Honduras 1
HR - Croazia 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MN - Mongolia 1
PA - Panama 1
PR - Porto Rico 1
RO - Romania 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
Totale 5.591
Città #
Santa Clara 305
Southend 303
Singapore 278
Ashburn 259
Fairfield 184
Chandler 164
Hefei 158
Dublin 138
Hong Kong 137
Ann Arbor 103
Woodbridge 103
Houston 77
Nyköping 77
Seattle 76
Beijing 70
Wilmington 69
Dearborn 62
London 62
Jacksonville 60
Bologna 57
Cambridge 57
Los Angeles 57
Modena 53
New York 43
Milan 42
Seoul 35
Ho Chi Minh City 32
Jakarta 31
Munich 31
Rome 30
Shanghai 28
Reggio Emilia 27
San Diego 25
Chicago 22
Hanoi 20
Bremen 18
Helsinki 18
Eugene 16
Princeton 16
Turku 16
Boardman 15
Moscow 15
Sofia 15
São Paulo 14
Council Bluffs 13
Frankfurt am Main 13
The Dalles 13
Brussels 12
Dallas 12
Florence 12
Parma 12
Turin 12
Redwood City 11
Nuremberg 10
Tokyo 10
Buffalo 9
Izmir 9
Kent 9
Redondo Beach 9
Denver 8
Falls Church 8
Lappeenranta 8
Mexico City 8
Salt Lake City 8
Warsaw 8
Amsterdam 7
Hillsboro 7
Palermo 7
Bari 6
Boston 6
Chengdu 6
Ferrara 6
Fulham 6
Poplar 6
Stockholm 6
Tampa 6
Belo Horizonte 5
Catania 5
Chennai 5
Fremont 5
Kunming 5
Monterrey 5
Montreal 5
Orem 5
Paris 5
Perugia 5
Piacenza 5
Roggiano Gravina 5
Sterling 5
Toronto 5
Atlanta 4
Augusta 4
Bogotá 4
Brescia 4
Buenos Aires 4
Des Moines 4
Dong Ket 4
Elk Grove Village 4
Formigine 4
Guangzhou 4
Totale 3.811
Nome #
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 432
Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: A randomized noninferiority trial 426
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 358
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 336
Efficacy of a multiple-component and multifactorial personalized fall prevention program in a mixed population of community-dwelling older adults with stroke, Parkinson's Disease, or frailty compared to usual care: The PRE.C.I.S.A. randomized controlled trial 310
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 294
"It's All COVID's Fault!": Symptoms of Distress among Workers in an Italian General Hospital during the Pandemic 270
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 254
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 229
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): A structured summary of a study protocol 226
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 225
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 224
Predictive role of capillaroscopic skin ulcer risk index in systematic sclerosis: a multicentre validation study 217
Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial 216
Biomarker expression and survival after primary chemotherapy for breast cancer. 193
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 184
Colchicine treatment in amyotrophic lateral sclerosis: safety, biological and clinical effects in a randomized clinical trial 152
Cosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial 145
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 142
Rapamycin treatment for amyotrophic lateral sclerosis protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial) 140
Physical activity practiced at a young age is associated with a less severe subsequent clinical presentation in facioscapulohumeral muscular dystrophy 137
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer 119
Pattern of distant relapse according to intrinsic molecular subtype in patients with HER2-positive breast cancer: a combined analysis of ShortHER, CherLOB, and two institutional cohorts 112
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â € "Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial 107
Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials 100
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis 98
Totale 5.646
Categoria #
all - tutte 22.188
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.188


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021302 0 0 0 0 0 20 44 46 45 84 48 15
2021/2022389 17 31 26 12 10 26 16 31 51 23 103 43
2022/2023651 53 61 40 46 57 62 16 50 195 12 27 32
2023/2024577 31 26 33 57 54 54 63 73 36 46 51 53
2024/20251.426 37 25 45 110 254 230 101 78 155 51 129 211
2025/20261.220 216 103 191 284 389 37 0 0 0 0 0 0
Totale 5.646